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Abstract
Background: We compared the effectiveness of self-expanding metal stent alone vs. radioactive stent embedded
with 125I seeds implantation insertion in patients of inoperable esophageal squamous cell cancer combined with
malignant esophageal stenosis.
Methods: We studied two groups of patients with stenosis attribute to inoperable esophageal squamous cell
carcinoma. Group A had placed self-expanding metal stent alone insertion; group B encountered radioactive stent
embedded with 125I seeds. Patients were followed up by monthly home visits or telephone interview. Survival time
was analyzed with Kaplan-Meier analysis. Log rank test was used to analyze factors of survival time for all
significant differences.
Results: There was no significant difference between the two groups of all baseline characteristics. There was no
statistical difference in complications including massive hematemesis, pain more than 1 month, stent migration,
and restenosis. Survival time and causes of death such as tumor metastasis, massive hemorrhage, non-tumor-related
factors, and restenosis were comparable between the two groups (P > 0.05). The medical costs were significantly less in
group A than those in group B (P < 0.01).
Conclusions: Radioactive stent embedded with 125I seeds was not significant in improving survival rate, but showed
to increase hospitalization costs compared to self-expandable metal stent alone in treating inoperable
esophageal squamous cell carcinoma stricture.
Keywords: Self-expanding metal stent, Intraluminal radioactive stent, Esophageal squamous cell carcinoma,
Malignant esophageal stricture, Clinical curative effect
Background
Esophageal cancer has a high morbidity and mortality
rate than other malignant tumors. Dysphagia is the most
common symptom in esophageal cancer, has serious im-
pact on nutrient intake, and threatens the lives of pa-
tients [1, 2]. More than half of the patients need
palliative treatment to relieve progressive esophageal
stricture [3]. To remove the stenosis of esophageal can-
cer and improve the quality of life of patients with
esophageal cancer, stent placement is the best choice to
improve the symptom caused by dysphagia [4–7]. In
1983, Frimberger [8] treated a patient diagnosed with
esophageal stricture placed with a metal stent. Metal
stents became more and more popular for patients who
encountered dysphagia [9, 10]. Recently, an esophageal
stent embedded with iodine-125 (125I) seeds (also called
intraluminal radiotherapy) has been developed [11, 12].
These two kinds of stents are more and more useful for
inoperable esophageal cancer [13–17]. Both stents have
been demonstrated as effective with few complications,
although their relative effectiveness is unknown. How-
ever, there was great controversy to self-expanding
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metal stent and intraluminal radioactive stent in clinical
curative effects, survival time, complications, hospital
stay, and cost [11, 12, 18–24]. In our study, the self-
expanding metal stent was compared with the radio-
active stent embedded with 125I seeds in treating inop-
erable esophageal squamous cell carcinoma.
Methods
Patients
The study was approved by the institutional ethics com-
mittee of the Affiliated Hospital of North Sichuan Medical
College. Informed consent was obtained from all enrolled
patients. A total 131 patients with inoperable esophageal
squamous carcinoma were selected for prospective non-
randomized study. Group assignment was based on physi-
cian’s professional assessment as well as the patient’s own
preference. Self-expandable metallic stent was performed
in 91 patients (group A) and intraluminal radioactive stent
was performed in 40 patients (group B) at the Affiliated
Hospital of North Sichuan Medical College between
September 2013 and June 2015.
The specific inclusion criteria were as follows:
1. The pathological diagnosis was esophageal
squamous cell carcinomas.
2. Stenosis by tumor invasion.
3. Physical fitness score (Karnofsky score) ≥ 50
4. Expected to survive no less than 1 month.
5. No other organs encountered serious dysfunction.
6. No chemotherapy or radiotherapy was performed
before and after stent implantation.
7. No chance to R0 resection for surgery (e.g., local
lymphadenomegaly; tumor had invaded adjacent
organ(s)).
The exclusion criteria were as follows:
1. Esophageal fistula.
2. The neck segment esophageal cancer.
3. Inability to obey follow-up.
4. Whatever the cause, stent placement was given up
halfway.
5. Esophageal adenocarcinoma and esophagogastric
junction carcinoma.
6. Patients rejected stent placement by personal
reasons.
Dysphagia score
Ogilvie’s dysphagia score classification is as follows:
grade 0, to be able to eat the ordinary diet; grade 1, to
be able to eat the solid food; grade 2, to be able to eat
the semisolids; grade 3, to be able to take liquids food;
and grade 4, to be able to eat nothing [25].
Stent and 125I seeds
The system of self-expanding metal stent contains two el-
ements: esophageal stent formed by nitinol and covered
by silicone membrane. Besides the two parts, intraluminal
radioactive stent is also composed of another nitinol
sheath outside of the stent, which can contain 125I seeds
(Nanjing Micro-tech Co., Ltd, Nanjing, China).
The radioactive seeds of 125I (Bejing ZHIBO Bio-
medical Technology Co., Ltd, Beijing, China) are wrapped
up in titanium alloy. Parameters of seeds are as follows:
4.5 mm, 0.8 mm, 60.1 days, 27–35 keV, 1.7 cm in length,
diameter, half-life, mean photon energy, and tissue pene-
tration. The original dosage rate was 7 cGy/h. Activity of
each seed for clinical use is 0.80–0.90 mCi.
Stent placement
Before stent placement, esophagoscope, computerized
tomography (CT), and barium meal was used to confirm
the tumor site, stricture degree, and length of tumor.
The parameters of the stent were assessed according to
the measured length of the tumor. The stent should be
chosen more than 2 cm at both ends of the tumor. The
stent implantation process of the two types of stents was
in the same method. The esophagus was able to select-
ively enlarge according to the degree of the esophageal
stenosis. Dilation was necessary when it was required to
place the stent to a maximum of 11 mm by a Savary-
Miller esophageal dilator (Changzhou Jiuhong Medical
Instrument Co., Ltd.).
Observation
Baseline characteristics were gender, age, tumor location,
complications before stent placement, local lymph node
enlargement (short diameter of lymph node ≥ 8 mm in
the cervical region, mediastinum, abdomen), tumor stage
(seventh edition of the AJCC and UICC), time of stent
placement, length of tumor, length of stent, and esopha-
gus dilation. Clinical curative effects were based on dys-
phagia score and tumor regression (smaller on the
maximum section area of CT). The complications were
sudden massive hemorrhage within the first month, pain
more than 1 month, stent migration, and restenosis.
Hospital stays and medical costs, survival time, and
death causes were also identified.
Followed up
Patients were followed up by monthly telephone inter-
view or home visits from a specialized doctor. All the
patients were followed up until July 2015 or death.
Statistical analysis
Statistical software package SPSS 22.0 (SPSS, Inc.,
Chicago, IL) was used for all the data analyses. Mean ±
standard deviation and range expressed the numeric data.
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Student’s t test, χ2 test, Kaplan-Meier method, and log-
rank test were applied in our study. P < 0.05 was consid-
ered to indicate a statistically significant difference.
Results
Patient characteristics
The median follow-up period in both groups A and B
were 4 months. Stent placement was successful in both
groups. The baseline characteristics of both groups were
detailed in Table 1. There were no statistically significant
differences in the gender, age, tumor location, complica-
tions before stent placement, local lymph node enlarge-
ment, tumor stage, time of stent placement, length of
tumor, length of stent, and esophagus dilation between
the two groups (P > 0.05).
Clinical curative effects
The dysphagia score was improved in the two groups after
stent placement. Three cases (7.5 %) of tumor growth
were inhibited in group B after 3 months, group A did
not, as shown in Table 2.
Complications
There were no statistically significant differences in the
sudden massive hemorrhage, pain more than 1 month,
stent migration, or restenosis in both groups (P > 0.05),
as shown in Table 3.
(1) Massive hemorrhage: No patient encountered sud-
den massive hemorrhage during stent placement, but
this complication developed in six (6.6 %) and one
(2.5 %) patients in group A and group B, respectively,
post placement; all of which were fatal.
(2) Pain: Most of the patients encountered retrosternal
pain after the stent placement and part of the patients
felt severe chest pain, which was relieved using narcotic
analgesics. Sixteen patients in group A and 12 patients
in group B felt severe pain more than 1 month, and no
statistically significant differences were identified be-
tween the two groups (P > 0.05).
(3) Stent migration: Five patients in group A and
two patients in group B experienced stent migration
2 months after stent placement, confirmed by elec-
tronic endoscopy or barium meal. Re-intervention by
Table 1 The baseline characteristics of studied groups
Characteristics Group A (n = 91) Group B (n = 40) P
Gender, n (%) 0.869c
Male 67 (73.6 %) 30 (75 %)
Female 24 (26.4 %) 10 (25 %)
Age (years, mean ± SD) (range) 66.3 ± 9.4 (43–90) 66.9 ± 8.6 (47–84) 0.700d
Location of cancer, n (%) 0.195c
Proximal third 15 (16.5 %) 3 (7.5 %)
Middle third 66 (72.5 %) 29 (72.5 %)
Distal third 10 (11.0 %) 8 (20.0 %)
Complications before stent placement, n (%) 0.601c
Yes 41 (46.1 %) 20 (50 %)
No 50 (55.9 %) 20 (50 %)
Local lymph node enlargement, n (%)a 0.686c
Yes 69 (75.8 %) 29 (72.5 %)
No 22 (24.2 %) 11 (27.5 %)
Tumor stage, n (%)b 0.437c
III 61 (67.0 %) 24 (60.0 %)
IV 30 (33.0 %) 16 (40.0 %)
Time of stent placement (min, mean ± SD) (range) 22.6 ± 4.9 (15–35) 20.2 ± 4.7 (14–32) 0.792d
Length of tumor (cm, mean ± SD) (range) 5.3 ± 1.3 (3–10) 5.5 ± 1.5 (2.5–8) 0.139d
Length of stent (cm, mean ± SD) (range) 9.3 ± 2.0 (6–16) 10.5 ± 1.6 (6–14) 0.274d
Esophagus dilation, n (%) 0.775c
Yes 57 (62.6 %) 24 (60 %)
No 34 (37.4 %) 16 (40 %)
aShort diameter of lymph node ≥8 mm in cervical region, mediastinum, abdomen
b7th edition of the AJCC&UICC
cχ2 exact test was used
dStudent’s t test was used
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gastroscope assistance was successful on these seven
patients.
(4) Restenosis: Four patients in group A and two patients
in group B experienced restenosis 3 months after stent
placement, confirmed by barium meal and/or gastroendo-
scopy. No patient chose to undergo further treatment.
(5) Others: There were no radioactive pneumonia,
bone marrow suppression, gastrointestinal reaction, and
other complications related to radiotherapy in group B.
Hospital stays and medical costs
The hospital stays were shorter in group A than those in
group B, but this did not reach statistical significance dif-
ference: 8.9 vs. 10.1 days, respectively (P > 0.05). The med-
ical costs were significantly less in group A than those in
group B: ¥7000 vs. ¥26,000, respectively (P < 0.01).
Survival time and death causes
The mean survival time in group A and group B was
4.2 ± 2.8 (0–15) months and 4.4 ± 2.4 (0–9) months, re-
spectively. The Kaplan-Meier curves were shown in
Fig. 1. There was no significant differences in the sur-
vival time (P = 0.752 > 0.05). The main death causes
were tumor metastasis (40.7 % vs. 40.0 %) and massive
hemorrhage (30.8 % vs. 27.5 %), as shown in Table 4.
Among these death causes, 96 patients (group A = 68,
group B = 28) died of esophageal cancer. The mean dis-
ease specific survival time in group A and group B was
3.4 ± 0.3 and 3.7 ± 0.4 months, respectively. The Kaplan-
Meier curves were shown in Fig. 2. There was no signifi-
cant difference in survival (P = 0.421 > 0.05).
Discussion
Advanced esophageal squamous cell carcinoma may
cause dysphagia. Dysphagia is the main symptom of pa-
tients with inoperable esophageal squamous cell carcin-
oma [1]. Most of them need the palliative care to relieve
this symptom [3].
Although esophageal bypass surgery has been per-
formed to enable oral ingestion, the outcome of this
palliative surgery is not always favorable because it is
extremely invasive for the patients in an unstable con-
dition as a result of advanced cancer [26–28]. In con-
trast, the insertion of an esophageal stent has many
advantages for such patients because it is much less
invasive and the procedure is simpler and safer than by-
pass surgery. Recently, stenting has been considered to
be the best way of treatment for malignant stenosis.
These work compared the self-expanding metal stent
alone and intraluminal radioactive stent loaded with 125I
seeds for palliation of dysphagia due to inoperable squa-
mous carcinoma of the esophagus.
Although various studies have described, intraluminal
radioactive stent got a better long-term clinical effect of
Table 2 Clinical curative effects
Group A (n = 85) Group B (n = 32) P
Ogilvie’s dysphagia score (prior stent placement), n (%) 0.997c
3 66 (72.5 %) 29 (72.5 %)
4 25 (27.5 %) 11 (27.5 %)
Ogilvie’s dysphagia score (post stent placement)a, n (%) 0.200c
0 73 (80.2 %) 28 (70.0 %)
1 18 (19.8 %) 12 (30.0 %)
Tumor regression, n (%)b 0.008c,d
Yes 0 (0 %) 3 (7.5 %)
No 91 (100 %) 37 (92.5 %)
a 3 days after stent implantation
b Smaller on the maximum section area of CT
c χ2 exact test was used
d P < 0.05 was considered to indicate a statistically significant difference
Table 3 Complications post to stent placement
Group A, n (%) Group B, n (%) P
Massive hemorrhagea 0.337b
Yes 6 (6.6 %) 1 (2.5 %)
No 85 (93.4 %) 39 (97.5 %)
Pain more than 1 month 0.110b
Yes 16 (17.6 %) 12 (30.0 %)
No 75 (82.4 %) 28 (70.0 %)
Stent migration 0.908b
Yes 5 (5.5 %) 2 (5.0 %)
No 86 (94.5 %) 38 (95.0 %)
Restenosis 0.879b
Yes 4 (4.4 %) 2 (5.0 %)
No 87 (95.6 %) 38 (95.0 %)
aIn the first month after stent placement
bχ2 exact test was used
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dysphagia and went with fewer complications. Moreover,
the median survival time was also longer in intraluminal
radioactive stent than self-expanding metal stent alone.
Our study showed no significance evidence of this fact
in inoperable esophageal squamous cell carcinoma.
All patients in our study were inoperable of advanced
esophageal cancer who chose self-expanding metal stent
(group A) and the radioactive stent embedded with 125I
seeds (group B) voluntarily. Both stent placements were
clinically successful. There was no death during stent
implantation.
The score of dysphagia was improved greatly in all pa-
tients after stenting, and there was no statistically signifi-
cant difference between groups A and group B. Three
months after stent placement, 4 patients in group A and
2 patients in group B experienced restenosis. The causes
of restenosis after placement may be due to the granula-
tion hyperplasia tissue and/or tumor tissue growing into
the ends of the stent [24]. No patient in our study
encountered restenosis because of the regrowth of the
tumor tissue.
Three months later, three cases (7.5 %) with tumor
growth was inhibited in group B, group A did not. This
demonstrated that the intraluminal radioactive stent had
the effect of inhibiting tumor growth and the hyperplasia
of the granulation tissue.
The main complications following the stent placement
include massive hematemesis, pain more than 1 month,
stent migration, and restenosis [13, 29–33]. There was
no statistical significance difference between group A
and group B in these outcomes.
Hemorrhaging after stent placement has been reported
about 3–8 % and most of the time was self-limited [1].
This incidence has also been reported as much as 30 %
in part of the study [11]. In our study, six patients in
group A and one in group B encountered massive hem-
orrhaging in 1 month after stent placement, but no pa-
tients succumbed during the process of stent placement.
Fig. 1 Intraluminal radioactive stent self-expanding metal stent. Kaplan-Meier curves of overall survival. Comparison of overall survival between
group A (self-expanding metal stent) and group B (intraluminal radioactive stent). The mean overall survival period was similar in group A compared
with that in group B: 4.2 ± 2.8 (0–15) months vs. 4.4 ± 2.4 (0–9)months, respectively. There was no significant difference in survival time (P > 0.05)
Table 4 Death causes
Death causes Group A (n = 86) Group B (n = 35) P = 0.959
Tumor metastasis, n (%) 37 (40.7 %) 16 (40.0 %)
Massive hemorrhage, n (%) 28 (30.8 %) 11 (27.5 %)
Non-tumor-related factors, n (%) 18 (19.8 %) 7 (17.5 %)
Restenosis, n (%) 3 (1.1 %) 1 (2.5 %)
χ2 exact test was used
Tian et al. World Journal of Surgical Oncology  (2016) 14:18 Page 5 of 8
In our study, most of the patients encountered retro-
sternal pain after the stent placement and part of the pa-
tients felt severe chest pain, which was relieved using
narcotic analgesics. Sixteen patients in group A and 12
patients in group B felt severe pain more than 1 month,
and no statistically significant difference was identified
between the two groups. That was lower than has been
observed in previous research (53.8 %) [34]. No patient
stopped stent treatment because of severe pain.
Five cases in group A and two cases in group B experi-
enced stent migration 2 months after stent placement,
confirmed by electronic endoscopy or barium meal.
Reintervention by gastroscope assistance was successful
on these patients. That should be due to the nature of
the nickel-titanium shape memory alloy stents. Cold
temperature will make the stent soften. When the
temperature reaches more than 37 °C for 1 week, the
stent will form a shape that does not change in response
to cold temperatures. In order to prevent the stent from
deformation or shifting, cold foods could be taken no
less than 1 week after stenting [24].
The hospital stays were shorter in group A than those
in group B, but there was no statistically significant dif-
ferences: 8.9 vs. 10.1 days, respectively. Few studies
reported hospital stays, but found longer compared to
those of our study. The medical costs were significantly
less in group A than those in group B: ¥7000 vs.
¥26,000, respectively. Some of other previous studies
found that there was no significant differences between
the total medical costs of metal stent placement vs.
radiotherapy in the palliative treatment of esophageal
squamous cell cancer [18, 19].
The mean survival time in group A and group B was
4.2 ± 2.8 (0–15) months and 4.4 ± 2.4 (0–9) months, re-
spectively. There was no statistical significance differ-
ence in survival time (P > 0.05). Besides, the disease-
specific survival better reflects the impact of stent place-
ment on the survival of patients. In this study, the mean
disease-specific survival time in group A and group B
was 3.4 ± 0.3 and 3.7 ± 0.4 months, respectively. There
was also no statistical significance difference in survival
(P > 0.05). The main death causes were tumor metastasis
(40.7 % vs. 40.0 %) and massive hemorrhage (30.8 % vs.
27.5 %). Although various studies [11, 12, 18, 35] have
described a longer survival time of intraluminal radio-
active stent than that of self-expanding metal stent, our
results showed no evidence of significance supporting
this fact in inoperable esophageal squamous cell cancer.
Fig. 2 Intraluminal radioactive stent, self-expanding metal stent. Kaplan-Meier curves of disease-specific survival. Comparison of disease-specific
survival between group A (self-expanding metal stent) and group B (intraluminal radioactive stent). The mean disease-specific survival period was
similar in group A compared with that in group B: 3.4 ± 0.3 months vs. 3.7 ± 0.4 months, respectively. There was no significant difference in
survival (P > 0.05)
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The reason of this difference may be attributed to differ-
ent case compositions. All the patients in our research
were only at advanced stage (III, IV stage) and esopha-
geal squamous cell carcinoma; however, other studies in-
cluded early/advanced stage (II, III, IV stage) patients
and esophageal adenocarcinoma/adenocarcinoma of the
esophagogastric junction.
Theoretically, radioactive stent embedded with 125I
seeds implantation may be better than self-expanding
metal stent alone insertion because of the different types
of stent to the tumor. Intraluminal radioactive stent pro-
vides closer, longer continuous radiotherapy with tumors.
Nevertheless, the dose of radiation with radioactive stent
in the esophageal lumen was too difficult to precisely
measure and plan. Therefore, an accurate dose of 125I
seeds was important. Unfortunately, there was no treat-
ment planning system (TPS) for luminal organs. The TPS
that we used mainly depended on the design of solid
tumors.
In the present study, the main death causes were
tumor metastasis and massive hemorrhage. Although
three cases of tumor growth were inhibited, there was
no significant effect of radioactive stent to inhibit tumor
metastasis and massive hemorrhage.
Some inevitable limitations also could be found in our
study. Firstly, the sample size of the present study was
considered small, although it reached the statistical sig-
nificance which could be due to the time limitation and
inclusion criteria. Our further studies with bigger sample
sizes may make more accurate results. Secondly, the
quality of life for these patients, an important measure
to assess for the palliative treatment of cancer, including
inoperable esophageal squamous cell cancer, was not
measured in our study.
Conclusions
Intraluminal radioactive stent embedded with 125I seeds
implantation was not significant when it came to the
outcome of survival benefit, but increased the
hospitalization expense than self-expandable metal stent
alone in treating inoperable esophageal squamous cell
carcinoma stricture.
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